As part of the preclinical safety evaluation process, an investigational macrolide antibiotic, LY281389, was examined for autonomic activity in isolated smooth and cardiac muscle preparations and for cardiovascular effects by intravenous infusion in anesthetized beagles. Concentration-dependent antagonism of acetylcholine and angiotensin I (guinea pig ileum), norepinephrine (rat vas deferens), and isoproterenol (guinea pig atria) was observed at LY281389 concentrations of -10-5 M. At LY281389 concentrations of _ 0-M, the response of the guinea pig ileum to electrical stimulation was also inhibited approximately 65 to 100%, indicative of potential anticholinergic or ot-adrenergic activity. In anesthetized dogs, the predominant effect of LY281389 was an increase in heart rate at doses of _200 ,ug/kg of body weight. LY281389 also produced slight increases in mean arterial pressure and shortening of the P-R interval of the electrocardiogram. In summary, LY281389 possesses nonselective receptor antagonist activity in vitro and produces cardiovascular stimulation in anesthetized dogs. These results indicate that, in addition to potent antimicrobial activity, the macrolide antibiotic LY281389 may exert unexpected actions on cardiovascular function.
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LY281389, chemically identified as 9-N-(n-propyl)erythromycylamine ( Fig. 1) , is a macrolide antibiotic with an in vitro spectrum of antimicrobial activity similar to that of erythromycin (7) . However, LY281389 is more stable than erythromycin in acidic environments. The oral bioavailability and effectiveness of LY281389 against infections in dogs and rodents is also superior to those of erythromycin. This improvement in efficacy may be related to higher levels of LY281389 in plasma and tissue compared with those of erythromycin.
The present studies were conducted to examine the acute cardiovascular and autonomic pharmacology of LY281389 in an attempt to examine potential secondary effects which might lead to preclinical or clinical alterations in cardiovascular function.
MATERIALS AND METHODS
Model design. (i) Isolated tissue preparations. Male SpragueDawley rats (180 to 600 g; Harlan Industries Inc., Indianapolis, Ind.) and male Hartley guinea pigs (250 to 350 g; Charles River Laboratories, Wilmington, Mass.) were killed by cervical dislocation.
All tissue preparations were placed in 10-ml organ baths containing Krebs' bicarbonate solution (4.6 mM KCI, 1.2 mM KH2PO4, 1.2 mM MgSO4, 118.2 mM NaCl, 10 .0 mM glucose, 1.6 mM CaCl2 .2H20, 24.8 mM NaHCO3). Tissue baths were maintained at 37°C and aerated with 95% 02 and 5% CO2. Resting tensions of 250 to 500 mg, 2 g, and 2 g were initially applied to the rat vas deferens and the guinea pig ileum and atrium, respectively. In some instances, isolated guinea pig ileum preparations were stimulated with squarewave pulses at supramaximal voltage (40 V, 0.7-ms duration, and 0.1 Hz). All of the tissues were allowed to equilibrate for approximately 1 force with the aid of a Beckman Dynograph recorder and Grass FT03 transducers.
(ii) Anesthetized dogs. Eight male beagles (approximately 10 kg) were pretreated with morphine sulfate (1.0 mg/kg of body weight; given subcutaneously), followed in approximately 1 h by sodium methohexital (Brevital) and alphachloralose (5 and 80 mg/kg, respectively; given intravenously). The following parameters were measured in the animals with the indicated equipment: femoral flow (Carolina Medical flow meter), blood pressure (Spectramed pressure transducer complete with heparin-filled cannula inserted into the left femoral artery), cardiac output (Swan-Ganz catheter and Instrumentation Laboratory Cardiac Output Computer), pulmonary arterial pressure and pulmonary capillary wedge pressure (Swan-Ganz catheter and Spectramed pressure transducer), and changes of electrical potential (lead II electrocardiograph) using pin electrodes. All recordings were made with a Beckman Dynograph recorder. The P-R, was constructed to examine potential antagonistic activity. For guinea pig ileum, LY281389 was added to the tissues and evaluated for agonist and antagonist (versus angiotensin I) activity as in the vas deferens. LY281389 was also compared with agents that inhibit the twitch response of the ileum (atropine and norepinephrine) and an agent that enhances the twitch response (physostigmine). LY281389 was also evaluated for antagonist activity against acetylcholine. For guinea pig atria (spontaneously beating), various concentrations of LY281389 were added to the tissues and evaluated for agonist and antagonistic (versus isoproterenol) activity as described for the tissues above. (Table 1) . LY281389 (10-3 M) antagonized the response of the rat vas deferens to norepinephrine but was inactive at lower concentrations (10'-and 10-5 M) (Fig. 2) . In the ileum isolated from guinea pig, LY281389 (10-3 M) completely antagonized the response to acetylcholine (Fig. 3a) and angiotensin I (Fig. 3b) . Lower concentrations (10-' and 10-5 M) produced weak shifts of the response of the ileum to these agonists (calculated pA2 values [pA2 = -log Kb] of LY281389 against acetylcholine and angiotensin I were 5.3 and 4.6, respectively). The antagonism appeared to be noncompetitive. Figure 3c demonstrates the capability of LY281389 to inhibit the response of the guinea pig ileum to field stimulation. LY281389 inhibited this response approximately 65 and 100% at 10-4 and 10-3 M, respectively. Figure 4 show the effects of LY281389 on the response of the spontaneously beating atria to isoproterenol. LY281389 (10-3 M) completely antagonized the positive inotropic ( Fig.   4a ) and chronotropic (Fig. 4b) (Table 2) . LY281389 (200 ,ug/kg/min, given intravenously; total dose of 10 mg/kg increased the mean arterial pressure and heart rate a maximum of 16 and 46%, respectively ( Fig. 5a and 5b) . The P-R interval was slightly decreased to a maximum of 11% at 50 min postinfusion (Fig.  Sc) . All other parameters (cardiac output, pulmonary capillary wedge pressure, pulmonary pressure, femoral flow, QRS, QT, QTC, stroke volume, stroke work index, pulmonary vascular resistance, and peripheral vascular resistance) were unchanged (data not shown).
DISCUSSION
New drug candidates are frequently identified in highly specific assays designed to target certain receptors or disease states. It therefore becomes increasingly important to verify the selectivity of new compounds in broad pharmacological profiling. Such profiling also serves to identify potential secondary activities which could result in functional side effects or toxicities in animals or humans. Antibiotics, in particular, are targeted to affect microorganisms and are therefore expected to be relatively inert from a pharmacological perspective. Thus, it was of interest to examine the potential cardiovascular and autonomic activities of the investigational macrolide antibiotic LY281389.
Studies in the anesthetized dog and in isolated smooth and cardiac muscle tissues revealed significant pharmacological effects of this macrolide antibiotic. Effects obtained in the anesthetized dog consisted of moderate increases in heart rate, slight increases in mean arterial pressure, and a slight decrease in the P-R interval. These effects were notable at doses as low as 200 ,ug/kg/min for 50 min. Tachycardia was substantiated in conscious dogs following oral administration of LY281389 (unpublished data). While cardiovascular effects of macrolide antibiotics have been reported (2, 8) , such effects are rare and are qualitatively different from those observed with LY281389. For example, hypotension has been described for the macrolide josamycin (2) , and disturbances in the QT interval have been reported with erythromycin (4, 9) . Erythromycin, however, has been reported to produce ventricular tachycardia (9) , which is consistent with effects observed with LY281389.
In isolated tissues, LY281389 antagonized all the receptor agonists tested (acetylcholine, angiotensin I, isoproterenol, norepinephrine, and oxytocin) at concentrations of 10-3 and 10-4 M and therefore appeared to be nonselective in its activity. While these concentrations are high from a pharmacological perspective, they are relevant with respect to antibiotic levels achieved in vivo. Ruterbories et al. (10) reported maximum drug concentrations in plasma of 0.26 and 1.5 ,ug/ml in rats and dogs, respectively, following oral administration of 10 mg of LY281389 per ml. Tissue levels achieved in heart and liver were 50 to 150 times those measured in plasma. These concentrations are in the range of those tested in isolated tissues. Similar to our findings with LY281389, negative inotropic and chronotropic effects of the macrolide josamycin have been described in the isolated rat atria (11) . It is possible that the anticholinergic activity of LY281389 observed in the guinea pig ileum could be involved in the elevated heart rate and blood pressure observed in the anesthetized dog. It is known, for example, that the anticholinergic agent atropine increases the heart rate in anesthetized dogs (1, 5) . The nonselective nature of the effects of LY281389 may indicate that at concentrations of-10-4 M, LY281389 may exert effects directly on smooth and cardiac muscle tissues.
In summary, significant effects of the investigational macrolide antibiotic LY281389 on autonomic and cardiovascular functions were detected in isolated tissues and the anesthetized dog. Relative to concentrations of LY281389 associated with antimicrobial activity, these results indicate the potential for cardiovascular effects of this antibiotic.
